X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.
Lead Product(s): Foslinanib,Sorafenib
Therapeutic Area: Oncology Product Name: CVM-1118
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TaiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 27, 2022
Details:
VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
Lead Product(s): VDA-1275,Sorafenib,Cisplatin
Therapeutic Area: Oncology Product Name: VDA-1275
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
OUTREACH-2 study evaluating MTL-CEBPA specifically up-regulates CCAAT/enhancer-binding protein alpha (C/EBP-α) in combination with sorafenib, in comparison to sorafenib alone, in up to 150 patients.
Lead Product(s): MTL-CEBPA,Sorafenib
Therapeutic Area: Oncology Product Name: MTL-CEBPA
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2022
Details:
The median sorafenib treatment duration was only nine weeks, a much shorter treatment duration than the referenced historical controls. The median treatment duration of TTFields was 10 weeks.
Lead Product(s): Sorafenib
Therapeutic Area: Oncology Product Name: Nexavar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
Last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
Lead Product(s): Sorafenib
Therapeutic Area: Oncology Product Name: Nexavar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.
Lead Product(s): MTL-CEBPA,Sorafenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The randomized, placebo-controlled Phase 2b study of YIV-906 is evaluating efficacy, safety, and quality of life in patients with hepatitis B-positive HCC.
Lead Product(s): YIV-906,Sorafenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Bora Pharmaceuticals- Making success more certain.
